Yissum - Research Development Company of the Hebrew University

Novel Activating Antibodies for Viral Treatment

Posted by Yissum - Research Development Company of the Hebrew UniversityResponsive · Innovative Products and Technologies · Israel

Summary of the technology

Novel Activating Antibodies for Viral Treatment
Project ID : 47-2020-10898

Yissum - Research Development Company of the Hebrew University

Description of the technology

Various pathogens (bacteria and viruses as well) bind to specific cell adhesion molecule in order to inhibit the immune response and/or to infect the host cells. However,upon binding and induction/activation, the cell adhesion molecule suppresses virus production by an SHP2-dependent process which involves also suppression of mTOR-mediated protein biosynthesis.

We propose our anti- cell adhesion molecule activating mAb as a broad antiviral therapy (including Covid-19) that will:

  • Bind the cell membrane cell adhesion molecule in various lung (i.e. endothelial, epithelial dendritic and other) cells and stimulate anti-viral activity in these lung cells expressing thecell adhesion molecule .
  • Bind and mask cell surface and virus associated cell adhesion molecule and render the possibility of Covid-19 cell adhesion molecule homotypic interaction with host cell and the following infection less feasible.

Project manager

Keren-Or Amar
VP, Business Development, Healthcare

Project researchers

Francesca Levi-Schaffer
HUJI, School of Medicine - IMRIC
School of Pharmacy- Institute for Drug Research

Related keywords

  • Virus, Virology / Antibiotics / Bacteriology
  • Biological Sciences
  • Infectious Diseases
  • Covid-19
  • Genetic Engineering / Molecular Biology
  • covid-19
  • viral treatment

About Yissum - Research Development Company of the Hebrew University

Technology Transfer Office from Israel

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.